ETH Zurich Scientists Propose Protein Biomarker Discovery Strategy Guided by Cancer Genetics
February 11, 2011
ETH Zurich Scientists Propose Protein Biomarker Discovery Strategy Guided by Cancer Genetics
Using the strategy, which is under development as a biomarker discovery platform at ETH Zurich spin-off firm ProteoMedix, the researchers have identified four protein biomarkers tied to prostate cancer.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- With $2.85M in Funding, ETH Zurich Spinout ProteoMedix Begins Validating Prostate Cancer Panel
February 10, 2012 / ProteoMonitor - Quanterix and Sony DADC Ink Co-Development Deal for SiMoA Consumables
July 22, 2011 / ProteoMonitor - Adarza Aims to Launch Biomarker Detection Platform Next Year; Adds Former Roche CEO to Board
June 3, 2011 / ProteoMonitor - Expanded Proximity Ligation Assay Could Prove Valuable for Biomarker Studies, Top-Down Proteomics
May 13, 2011 / ProteoMonitor - Magnetic Biosensor Could Enable Simultaneous Monitoring of Thousands of Protein-Ligand Bindings
May 6, 2011 / ProteoMonitor